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Abstract 
Chronic spontaneous urticaria (CSU) is a skin disease related to autoreactive IgE in at least a 
subgroup of patients. However, the nature of this autoreactive IgE remains poorly characterized. 
This investigation had three objectives: first, to quantity CSU autoreactive IgE; second, to recognize 
the patterns of CSU autoreactive IgE compared with healthy control IgE; and third, to investigate the 
physiochemical nature of CSU autoreactive IgE. 
Methods: IgE autoreactivity was assessed in sera from 7 CSU and 7 healthy individuals. Autoantigen 
recognition patterns were assessed using principal component analysis (PCA) and heatmap 
visualization. Lipophilicity was assessed using NanoOrange reagent. 
Results: First, although total IgE levels did not differ significantly, the autoreactive proportion of IgE 
of CSU patients was 62% ± 37%, 1000-fold higher than that of healthy controls 0.03% ± 0.008% (P = 
0.0006). Second, CSU autoreactive IgE differed from healthy control IgE by recognizing more and 
different autoantigens (226 vs. 34; P = 0.01). Third, the median (with 10–90% percentiles) serum 
level of lipophilic IgE was 39% (38–40%) in 232 CSU patients, 1.4-fold higher than the 28% (26–29%) 
of 173 healthy controls (P < 0.0001). Furthermore, lipophilicity correlated with autoreactivity (r = 
0.8; P < 0.0001), connecting these two observed features. 
Conclusion: We believe that these novel observations about CSU autoreactive IgE, particularly 
the finding that it is more lipophilic than that of IgE from healthy individuals, will lead to the 
development of new diagnostic tests and therapies for autoreactive IgE-mediated diseases. 
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Introduction 
Chronic spontaneous urticaria (CSU) is an 
itching, mast cell-driven skin disease characterized by 
the recurrence of transient wheals, angioedema, or 
both for more than six weeks [1]. Although CSU is a 
multifactorial condition involving autoimmunity, 
coagulation and inflammation [2], IgE-mediated 
autoimmunity, or autoallergy, is thought to play a 
major role [3, 4]. This is supported by the following 
evidences: (i) clinical effectiveness of omalizumab 
(anti-IgE) in relieving the symptoms of CSU; (ii) 
scientific observations that CSU patients have higher 
levels of total IgE than healthy individuals; and (iii) 
elevated levels of IgE are directed, for example, to 
thyroid antigens and double-stranded DNA [5, 6]. The 
last mentioned of these observations has been 
extended recently by the finding in CSU patients, 
using protein microarray analysis, of over 200 
IgE-autoantigens that are not recognized by healthy 
controls and that IL-24 is a common, specific, and 
functional autoantigen of IgE antibodies in patients 
with CSU [7]. 
Considering the stronger and broader response 
to autoallergens in CSU patients as compared with 









subset of patients, an autoallergic disease in which 
most of the IgE could be of an autoreactive nature. 
This is of clinical relevance as autoreactive IgE 
correlates with severity of disease [4] and results in 
therapeutic consequences [8]. A closer understanding 
of autoreactive IgE in CSU will pave the way for the 
development of new diagnostic tests and therapies 
that will increase the effectiveness of management of 
the disease.  
While the amino acid composition and the 
resulting physicochemical properties of allergens are 
quite diverse, cross-reactive, multi-specific IgE has 
been shown to favour lipophilic ligand-binding inter-
actions [9, 10]. As autoreactivity is often accompanied 
with cross-reactivity [11, 12], we postulate that the 
corresponding autoantibody will also be lipophilic. 
 In this project, we reanalysed a large screening 
database of autoreactive IgE in CSU patients [7] to 
calculate total autoreactive IgE levels. Also, we 
developed an IgE-lipophilicity assay using the fluor-
escent dye NanoOrange, which binds to lipophilic 
regions of proteins, resulting in an enhancement of 
fluorescence [13, 14], to determine lipophilicity of IgE 
from CSU patients and healthy controls. 
Methods 
Sera collection 
Sera from a total 239 CSU patients (57.1% female) 
and 180 healthy controls (53.8% female) were used in 
this study. There were no significant differences 
between the ages of the CSU patients (median 44, 
range 15 to 82 years) and healthy controls (median 35, 
range 20 to 64 years). Seven representative CSU 
patients (5 female) from the study population and 
seven age- and sex-matched healthy controls were 
chosen for auto-IgEome-analysis using microarray 
screening and IgE-anti-IL-24 measurement. The 
IgE-lipophilicity assay was performed on the 
remaining 232 CSU patients and 173 healthy controls. 
Additional IgE-anti-IL-24 measurements were 
performed on 27 CSU patients randomly selected 
from the study population. 
CSU patients were recruited from our 
specialized outpatient clinic for Dermatological 
Allergology at Charité–Universitätsmedizin Berlin. 
They had been diagnosed with CSU in line with the 
current EAACI/GA2LEN/EDF/WAO urticaria 
guideline [1]. The mean duration of CSU was 5.8 ± 6.5 
years and the mean seven-day urticaria activity score 
[1] was 25 ± 9. All had been treated previously with 
H1-antihistamines. None had received treatment with 
anti-IgE or similar agents. 
Blood was taken from all study subjects and 
serum separated after clot formation without the use 
of a clotting enhancer. After separation, serum was 
frozen immediately and stored at -80 °C until use. 
Blood samples taken from patients and all 
material investigated in this study were used after 
written informed consent was obtained, as approved 
by the ethics committee of the Charité-Universität-
smedizin Berlin (EA1-329-14 and EA1-292-14) 
according to the Declaration of Helsinki (59th WMA 
General Assembly, Seoul, October 2008). 
Calculation of total autoreactive IgE levels 
To assess serum autoallergen levels, we reanaly-
sed the Auto-IgEome data base, which has been 
published previously [7]. Total IgE levels measured 
by the Central Laboratory of Charité–Universitätsme-
dizin Berlin were used to calculate the percentage of 
autoreactive IgE.  
Visualisation of autoantigen recognition 
patterns 
Principal Component Analyses (PCA) and 
heatmap visualisation were performed using 
‘ClustVis’ [15]. IgE-binding signals to 9374 full-length 
human proteins as assessed by microarray [7] from 
seven CSU patients and seven healthy controls were 
analysed by PCA. Singular value decomposition was 
used to calculate principal components (PC). The 
PCA-plot shows PC1 and PC2 indicating 24% and 
18.2% of the total variance, respectively. Mean values 
of the IgE-binding signals for each autoantigen were 
calculated separately for each sample from both CSU 
patients and healthy controls. Thirty autoantigens 
with the highest mean total IgE-binding signal from 
each group were chosen to generate a heat map and a 
dendrogram (average linkage). IgE-binding signals 
were expressed as Z-scores. The rows were labelled 
with the corresponding GenBank identification 
number for each autoantigen.  
IgE-lipophilicity Assay 
Sixteen micrograms of anti-IgE (MHE-18, Bioleg-
end, San Diego, USA) was dispensed in 10 mL 
Coating Buffer (0.1 M carbonate at pH 9, Merck, 
Darmstadt, Germany) and 25 μL of this solution was 
used to coat each well of a black NUNC Maxisorb 
384-well plate (Thermofisher, Waltham, USA) at 4 °C 
overnight. After blocking with 2% human albumin 
(clinical grade, Baxter, Unterschleißheim, Germany) 
in TPBS (PBS with 0.05% Tween-20, Merck) overnight 
at 4 °C, 25 μL human serum was added per well with 
four replicates and incubated 1 h at room temperature 
followed by three washes with TPBS and two washes 
with water. NanoOrange (Thermofisher) dye was 
processed according to the product instructions 
(NanoOrange Protein Quantitation Kit, Thermo-
fisher). 5 mL of 1× NanoOrange reagent working 





solution was prepared and 10 μL of this solution was 
used per well (without previous heat denaturation of 
the sample) and incubated for 30 min at room 
temperature in the dark. The plates were measured in 
a Victor V reader (Perkin Elmer, Waltham, USA) with 
standard settings and the results are expressed as 
counts per second. The percentage of the signal from 
the maximum signal (maximum signal was set to 
100%) of each test was calculated to normalize results 
from different reproductions. 
IgE-anti-IL-24 measurements  
The results from the IgE-anti-IL-24 ELISA with 
units calculated as previously described [7] were used 
for further analyses. The ratios of IgE-anti-IL-24 to 
total IgE were calculated as relative levels. 
Statistical analyses 
Normal distribution was tested using 
D'Agostino-Pearson omnibus test and an approxim-
ately Gaussian distribution served as the basis to 
perform Student’s t-tests corrected for multiple 
testing by the Holm-Sidak method. The null 
hypothesis of random results was rejected if the 
P-value was < 0.05. Statistical differences between 
results that were not normally distributed were 
calculated using the Mann Whitney U test.  
Results 
The majority of IgE in CSU patients is 
autoreactive IgE 
Total IgE levels of the CSU patients and healthy 
controls did not differ significantly and were 85 ± 61 
and 144 ± 115 IU/mL respectively (Figure 1A). The 
corresponding mean autoreactive IgE levels, 
calculated by summing the total amount of IgE 
binding after standardizing the microarray signals 
with the IgE-anti-IL-24 ELISA, were 37.038 ± 23.916 
IU/mL for CSU patients and 0.047 ± 0.039 IU/mL for 
healthy controls. This difference of ~1000-fold was 
highly significant (P = 0.001). The absolute amount of 
autoreactive IgE was comparable in all CSU patients 
(Figure 1A) and there was no correlation between 
autoreactive IgE and total IgE (r = 0.16, P = 0.73, data 
not shown). The relative concentration of autoreactive 
IgE (expressed as a percentage of total IgE) in CSU 
patients was 60.96% ± 32.996%, with two patients 
having 100% of their IgE being autoreactive. In 
contrast, the relative concentration of autoreactive IgE 
in healthy controls was only 0.03% ± 0.008%. This two 
thousand-fold difference was highly significant (P = 
0.0006). IgE from CSU patients recognized 
significantly more autoantigens as compared to 
healthy controls (total number of 226 vs. 34; P = 0.01; 
Figure 1B). However, the maximum number of 
autoantigens detected by IgE in a single CSU patient 
was 197 compared to 34 in healthy controls. 
IgE from CSU patients and healthy controls 
recognise a different set of autoantigens 
A heat map visualization of the 30 most often 
recognised, but not necessarily the strongest, 
autoantigens of IgE from seven CSU patients and the 
30 most often recognised autoantigens by IgE from 
seven healthy controls is shown in Figure 2A. Cluster 
analysis of these 60 autoantigens results in two 
different autoantigen groups with little crossover, as 
indicated by the dendrogram. Visualization of 
IgE-binding signals to all 9374 full-length human 
proteins tested using PCA shows again two different 
autoantigen groups. The CSU patients form a more 
heterogeneous group, indicated by the wide spread of 




Figure 1. CSU patients exhibit high amounts of autoreactive IgE. (A) 
Logarithmic plot showing total IgE levels (total column length) and autoreactive IgE 
levels (black areas of columns) of seven CSU patients and seven healthy controls. (B) 
The mean number of autoantigens recognized by IgE from seven CSU patients (95 ± 
66) and seven healthy controls (28 ± 12) were significantly different (P = 0.01, Mann 
Whitney U test). 
 
Increased lipophilicity is a feature of IgE in 
CSU patients 
Levels of lipophilic IgE (expressed as a 
percentage of the maximum signal) were assessed in 
three independent reproductions. The pooled data 
with a total of 232 tested CSU patients and 173 healthy 
controls are shown in Figure 3. The median (with 
10–90% percentiles) serum level of lipophilic IgE was 
39% (38–40%) in CSU patients, 1.4-fold higher than 
the 28% (26–29%) in healthy controls (P < 0.0001, 
Figure 3A-B). ROC-analysis showed a sensitivity of 
80% and specificity of 72% (pooled data, Figure 3C) 
for elevated lipophilicity (cut-off 31% of maximum 
signal) as determined by use of the Youden Index. 





Correlation between autoreactive IgE and 
IgE-anti-IL-24  
The mean (± SEM) relative IgE-anti-IL-24 level of 
15.26×10-3 ± 21.57×10-3 in CSU patients was 
significantly (P = 0.0006) higher than the 0.06×10-3 ± 
0.04×10-3 in healthy controls (Figure 4A). Relative 
total autoreactive IgE levels (a ratio of summed total 
microarray binding IgE divided by total IgE) 
correlated significantly with absolute IgE-anti-IL-24 
levels (r = 0.847, P = 0.0001) as well as with relative 
IgE-anti-IL-24 levels (r = 0.656, P = 0.0108, Figure 4B) 
in 14 tested individuals (seven CSU patients and 
seven healthy controls).  
IgE-lipophilicity correlates with autoreactive 
IgE in CSU patients 
The ratio of lipophilic IgE to total IgE correlated 
highly significantly with relative IgE-anti-IL-24 levels 




Figure 2. IgE from CSU patients detects a different group of autoantigens than IgE from healthy controls. (A) Heat map visualization of the 30 most recognized 
autoantigens by IgE from seven CSU patients and the 30 most recognized autoantigens by IgE from seven healthy controls. The arrow indicates IL-24 among the CSU 
autoantigens. Z-scores specify IgE binding to autoantigens measured by microarray. Autoantigens that show similar detection patterns were clustered together, as indicated by 
the dendrogram on the left. (B) Principal component analyses of IgE-binding signals to 9374 human proteins from seven CSU patients and seven healthy controls. The PCA-plot 
shows PC1 and PC2 explaining 24% and 18.2% of the total variance, respectively. Prediction ellipses are drawn such that a new observation from the same group will fall inside 
the ellipse with a probability of 0.95. 






Figure 3. Signal intensity to assess lipophilic IgE is significantly higher in CSU patients than healthy controls. (A) Box plots (with 10-90% percentiles) showing 
that the median serum level of lipophilic IgE in 232 CSU patients is approximately 1.4-fold higher than that of 173 healthy controls. The significance of this difference is P < 0.0001 
(Student’s t-test). The blot shows pooled data from three independent reproductions with separate populations and similar results. (B) Histogram showing frequency 
distributions of lipophilic IgE signals (pooled data) from patients with CSU and healthy controls. (C) Receiver operating characteristic curve of three reproductions and pooled 
data from all measurements. 
 
Figure 4. Relative autoreactive IgE is associated with higher relative IgE-anti-IL-24 levels. IgE is more lipophilic in sera with higher amounts of autoreactive IgE. (A) 
The mean relative IgE-anti-IL-24 levels (ratio of IgE-anti-IL-24 to total IgE levels) are two log-scales higher in seven CSU patients than in seven healthy controls. The significance 
of this difference is P = 0.0006 (Mann Whitney U-test). (B) Percentage of autoreactive IgE (from total IgE) correlates with relative IgE-anti-IL-24 levels (N = 14; Pearson 
correlation coefficient, r = 0.656; P = 0.0108) in combined data from patients with CSU (black circles, N = 7) and healthy controls (open circles, N = 7). (C) The relative level 
of IgE-anti-IL-24 was used as a surrogate marker for the whole autoreactive IgE concentration. There is a strong correlation between the ratio of lipophilic IgE to total IgE and 
the ratio of IgE-anti-IL-24 to total IgE in CSU patients (N = 27; Pearson correlation coefficient, r = 0.754; P < 0.0001). 
 
Discussion 
This study on the nature of autoreactive IgE in 
CSU had three major findings: First, the majority of 
IgE in CSU patients is autoallergic IgE. Second, the 
IgE of CSU patients recognizes a completely different 
set of autoantigens than the IgE of healthy controls. 
Third, the IgE of CSU patients is more lipophilic than 
that of healthy controls. 
The list of diseases in which IgE autoantibodies 
have been identified is growing and includes atopic 
dermatitis, pemphigus vulgaris, systemic lupus 
erythematosus and bullous pemphigoid [4]. Determi-
nation of autoreactive IgE levels is of great interest as 
there is a significant correlation with disease activity 
[16-19], and autoreactive IgE has implications for 
therapeutic decision making, for example whether to 
use omalizumab (anti-IgE) in bullous pemphigoid [8]. 
In CSU, the prevalence of autoreactive IgE to tissue 
factor and thyroglobulin is linked to disease activity 
and is decreased after disease remission following 
omalizumab treatment [20]. Calculation of the 





concentration of autoreactive IgE in the sera of CSU 
patients revealed that it comprised a mean of over 
60% of total IgE compared with 0.03% in sera from 
healthy controls. Similar high amounts of reactive IgE 
have been reported previously in patients allergic to 
hydrophobic cyclohexenyl drugs such as propofol 
[21]. These striking results show the impact of IgE 
autoantibodies in CSU and the importance of 
understanding this immune dysregulation. 
The results show that the absolute amounts of 
autoreactive IgE were similar in all CSU patients and 
independent from their total IgE levels. This is 
comparable to previous studies demonstrating 
independence of drug-reactive IgE from total IgE 
levels [21]. There are several possible explanations for 
the high, but relatively consistent, levels of 
autoreactive IgE in CSU. First, IgE production by B 
cells is controlled in general by an inhibitory feedback 
mechanism mediated by binding of IgE to CD23 [22]. 
Second, as autoreactive antibodies are often produced 
as natural antibodies by B1 B cells, the homeostatic 
control of those cells might set a maximum amount of 
autoreactive IgE that can be produced [23, 24].  
The large difference between autoreactivity of 
IgE from CSU patients and healthy controls is an 
outstanding feature compared with autoreactive IgG 
patterns [25-30]. However, allergic IgE shows a simil-
ar pattern [31]. Full sets of antigens are recognized by 
IgE from certain individuals, suggesting polyreactive 
IgE [32]. As IgE, and especially autoreactive IgE, is 
polyreactive [33, 34], it is possible that one or a few 
IgE clones are present in healthy controls, which are 
reactive against the set of autoantigens, or that there 
are many auto-IgE clones, each one being specific for 
one or a few autoantigens. However, as almost all of 
this “normal” autoreactive IgE is not present in CSU 
patients anymore and a completely new pattern of 
reactivity is visible, it is more likely that there is only a 
very limited number of autoreactive IgE clones 
present, which are poly-autoreactive and which 
change or are removed as CSU ensues. It is less likely 
that suddenly all of many normal auto-IgE clones are 
nearly completely gone in CSU and replaced by a full 
new set of many CSU auto-IgE clones. 
Another major finding in this study is the 
increased lipophilicity of IgE in CSU patients 
compared to IgE of healthy controls. Lipophilic IgE 
has been previously found in patients allergic to 
lipophilic drugs and in patients suffering from AD but 
not in healthy controls [21]. Lipophilicity of IgE in 
these patients was explained by lipophilic antigen 
epitopes that result in cross reactivity to other 
lipophilic drugs due to similarities with epitopes 
binding specific IgE [21]. Cross-reactivity was also 
observed between the two lipophilic allergens fel d7 
and can f1 [35], although it is questioned whether 
general lipophilic stickiness is alone responsible for 
cross-reactivity of IgE [36]. However, increased 
lipophilicity of IgE in CSU patients and the resulting 
cross-reactivity might explain the association of CSU 
with hypersensitivity to mugwort and other 
aeroallergens [37], Staphylococcus aureus enterotoxins 
[38] and hydrophobic drugs like penicillin [39] 
leading to increased risk of anaphylactic reactions.  
For further analyses of these two observed 
features, we used IgE-anti-IL-24 as a surrogate marker 
for autoreactive IgE. Instead of absolute IgE levels, we 
used relative total IgE levels as they better reflect the 
physiological conditions and distribution of IgE 
bound to mast cells [40]. IgE lipophilicity correlates 
highly significantly with this surrogate marker, 
suggesting a connection between the autoreactivity 
and lipophilicity of IgE in CSU patients. This may be a 
future parameter for general autoreactivity of IgE. As 
mentioned above, increased lipophilicity of IgE was 
also found in patients with atopic dermatitis [21], and 
this disease is known to be associated with IgE 
autoantibodies against more than 140 autoantigens 
[41]. Other studies found a tendency for lipophilic 
immunoglobulin heavy chain complementary- 
determining regions 3 loops to cause autoreactivity 
[12, 42, 43]. As the specificity of IgE in patients allergic 
to grass pollen is mainly determined by the heavy 
chains [34, 44], the autoreactivity might be due to a 
preferred heavy chain that is lipophilic. A similar 
phenomenon was observed for anti-nuclear antibod-
ies as an example of an autoantibody. Although they 
can derive from almost every heavy chain variable 
domain gene family, most of them utilize one out of 
just four different preferred heavy chain variable 
domain families [45].  
In conclusion, in this study we have shown that, 
unlike in healthy individuals, the majority of IgE in 
CSU patients is autoallergic IgE and that this IgE 
recognises a different spectrum of autoantigens than 
that of IgE from healthy individuals. Furthermore, we 
have shown that the autoallergic IgE of CSU patients 
is more lipophilic than that of healthy individuals. We 
believe that this last finding in particular will pave the 
way for the development of new diagnostic tests and 
therapies that will increase the effectiveness of 
management of CSU. 
Abbreviations 
auto-IgE: autoreactive IgE; CSU: chronic 
spontaneous urticaria; IgE-anti-IL-24: IgE reactive to 
IL-24; IL-24: interleukin-24; PC: principal component; 
PCA: principal component analyses; ROC: receiver 
operating characteristic; TPBS: PBS with 0.05% 
Tween-20. 
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